United States · 
What does Omega Funds invest in?
Omega Funds invests most often at Series A and Series B (63% of the rounds on record), in sectors such as Oncology, Immunology and Rare_diseases.
Omega Funds highlights
- 01
17 cheques in the last 12 months
- 02
Mostly Series A and Series B: 63% of its rounds
- 03
Sole investor in 5 rounds, median $2.6M
- 04
1 exits from the portfolio
What they do
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others.From their own website
- Type
- VC firm
- Cheque size
- Not stated
- Stages
- BuyoutGrowthPre-seedSeedSeries ASeries B
- Sectors
- OncologyImmunologyRare_diseases
- Based in
- Boston, United States
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first104 appearances
- 2026
14 rounds
- Sept
- Sept
- Aug
- May
- May
- Apr
- Apr
- Feb
- Feb
- Jan
- Jan
- Jan
- Jan
- Jan
- 2025
14 rounds
- Dec
- Dec
- Dec
- Sept
- Jul
- Jun
- May
- May
- May
- Apr
- Mar
- Mar
- Jan
- Jan
- 2024
9 rounds
- Nov
- Nov
- Aug
- Jul
- Jul
- Jul
- Jun
- May
- Apr
- 2023
8 rounds
- Nov
- Nov
- Jul
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration9 named
ARAlexandra Rankel PearsallChief Financial OfficeriForm ADV
APAnne-Mari PasterDirectoriFiling they signed
CPClaudio Pier Antonio NessiManager & MemberiForm ADV
FLFrancesco Luigi DraettaManager & MemberiForm ADV
KBKevin BrennanA Director of the general partner of the General PartneriFiling they signed
MEMark Emerson RussellChief Compliance OfficeriForm ADV
O(Otello (nmn) StampacchiaA Director of the general partner of the General PartneriFiling they signed
RLRichard LimDirectoriFiling they signed
SASharon AlvarezA Director of the general partner of the General PartneriFiling they signed
We also hold 16 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$1.7Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- Omega Fund Management, LLC
- SEC number
- CRD 157753
Funds on its Form ADV
8 private funds, $694M in gross assets · filed Mar 2024
- Omega Fund VII, L.P.Private equity87 investors$324M
- Omega Fund VI, L.P.Private equity45 investors$268M
- Omega Fund V, L.P.Private equity34 investors$68M
- Omega Fund IV, L.P.Private equity37 investors$29M
- NET Assets of Omega Fund III, L.P.Private equity15 investors$3.1M
- Omega Fund II, L.P.Private equity6 investors$1.7M
- Life Sciences Holdings SPV I Fund, L.P.Private equity1 investor$190K
- Omega Fund VIII, L.P.Private equity42 investors-
What they claim to have backed
From their own portfolio page (on their website)
0 of 4 we have independently watched raise
Omega Fund VS3Show + TellSscfundservices
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed1 in all
Santaris PharmaBought by Roche$450MAug 2014
An exit counts when it came after the firm's first round in the company. From historical deal records.